Advertisement

Impact of the homogeneous and heterogeneous risk factors on the incidence and survival outcome of bone metastasis in NSCLC patients

  • Qian Song
  • Jun Shang
  • Chufan Zhang
  • Lanlin Zhang
  • Xianghua WuEmail author
Original Article – Clinical Oncology
  • 36 Downloads

Abstract

Purpose

Bone metastases (BM) is reported as the most frequent distant metastasis in non-small cell lung cancer (NSCLC), but the risk factors for the incidence and prognosis of BM patients in NSCLC have not been extensively elucidated. This study aimed to find risk factors to predict BM patients’ morbidity and survival outcome in NSCLC.

Methods

63,505 patients of NSCLC in the Surveillance, Epidemiology and End Results database diagnosed from 2010 to 2015 were used to analyze risk factors for developing BM by conducting multivariable logistic regression. Of these patients, 6152 and 5664 BM patients diagnosed between 2010 and 2014 were selected to investigate predictive factors for BM overall survival (OS) and cancer-specific survival (CSS) using the multivariable Cox proportional hazards regression.

Results

There were overall 7486 (11.79%) BM patients in NSCLC. The homogeneous risk factors for BM patients’ morbidity and survival outcome included male, higher T stage, lymph node involvement, poor differentiation grade, brain metastases, and liver metastases. Married status, adenocarcinoma type and lung metastases were positively correlated with BM incidence, while older age, white race, unmarried status, and SCC and other NSCLC types could predict poor OS and CSS of BM in NSCLC.

Conclusions

The homogeneous and heterogeneous risk factors for morbidity and survival outcome of BM patients could help physicians in more precise and individualized screening and therapies for BM patients in NSCLC.

Keywords

Non-small cell lung cancer Bone metastasis Risk factors Morbidity Prognosis 

Abbreviations

BM

Bone metastases

NSCLC

Non-small cell lung cancer

US

The United States

SEER

Surveillance, epidemiology and end results

OS

Overall survival

CSS

Cancer-specific survival

SREs

Skeletal-related events

NCCN

National comprehensive cancer network

K-M

Kaplan–Meier

OR

Odds ratio

CI

Confidence interval

MST

Median survival time

Notes

Acknowledgements

This study would like to thank the author’s lover Yue Zhang for her love, support and encouragement.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. Aizer AA et al (2013) Marital status and survival in patients with cancer. J Clin Oncol 31:3869CrossRefPubMedCentralGoogle Scholar
  2. Costa L, Badia X, Chow E, Lipton A, Wardley A (2008) Impact of skeletal complications on patients’ quality of life, mobility, and functional independence supportive care. in cancer Off J Multinatl Assoc Support Care Cancer 16:879–889.  https://doi.org/10.1007/s00520-008-0418-0 CrossRefGoogle Scholar
  3. Erturan S, Yaman M, Aydin G, Uzel I, Musellim B, Kaynak K (2005) The role of whole-body bone scanning and clinical factors in detecting bone metastases in patients with non-small cell. Lung Cancer Chest 127:449–454.  https://doi.org/10.1378/chest.127.2.449 Google Scholar
  4. Gomez SL et al (2016) Effects of marital status and economic resources on survival after cancer: a population-based. Study Cancer 122:1618–1625CrossRefGoogle Scholar
  5. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, Paz-Ares L (2017) Lung cancer: current therapies and new targeted treatments Lancet (Lond Engl) 389:299–311.  https://doi.org/10.1016/s0140-6736(16)30958-8 CrossRefGoogle Scholar
  6. Kuchuk M, Addison CL, Clemons M, Kuchuk I, Wheatley-Price P (2013) Incidence and consequences of bone metastases in lung cancer patients. J Bone Oncol 2:22–29.  https://doi.org/10.1016/j.jbo.2012.12.004 CrossRefPubMedCentralGoogle Scholar
  7. LeVasseur N, Clemons M, Hutton B, Shorr R, Jacobs C (2016) Bone-targeted therapy use in patients with bone metastases from lung cancer: a systematic review of randomized controlled trials. Cancer Treat Rev 50:183–193.  https://doi.org/10.1016/j.ctrv.2016.09.013 CrossRefGoogle Scholar
  8. Morgensztern D, Waqar S, Subramanian J, Gao F, Trinkaus K, Govindan R (2012) Prognostic significance of tumor size in patients with stage III non-small-cell lung cancer: a surveillance, epidemiology, and end results (SEER) survey from 1998 to 2003 J Thorac Oncol 7:1479–1484.  https://doi.org/10.1097/JTO.0b013e318267d032 CrossRefGoogle Scholar
  9. Quint LE et al (1996) Distribution of distant metastases from newly diagnosed non-small cell lung cancer Ann Thorac Surg 62:246–250CrossRefGoogle Scholar
  10. Riihimaki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer Lung Cancer (Amst Neth) 86:78–84.  https://doi.org/10.1016/j.lungcan.2014.07.020 CrossRefGoogle Scholar
  11. Siegel RL, Miller KD, PhD AJD (2018) Cancer statistics, 2018 CA: Cancer J Clin 68:11Google Scholar
  12. Tanvetyanon T, Hines E Jr (2005) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other. Solid Tumors Cancer 103:1756–1757.  https://doi.org/10.1002/cncr.20996 (author reply 1757–1758)Google Scholar
  13. Torok JA, Gu L, Tandberg DJ, Wang X, Harpole DH Jr, Kelsey CR, Salama JK (2017) Patterns of distant metastases after surgical management of non-small-cell lung cancer Clin Lung Cancer 18:e57-e70  https://doi.org/10.1016/j.cllc.2016.06.011 CrossRefGoogle Scholar
  14. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012 CA: Cancer J Clin 65:87–108.  https://doi.org/10.3322/caac.21262 Google Scholar
  15. Tsuya A, Kurata T, Tamura K, Fukuoka M (2007) Skeletal metastases in non-small cell lung cancer: a retrospective study Lung Cancer (Amst Neth) 57:229–232.  https://doi.org/10.1016/j.lungcan.2007.03.013 CrossRefGoogle Scholar
  16. Wood DE et al (2018) Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 16:412–441.  https://doi.org/10.6004/jnccn.2018.0020 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Medical OncologyFudan University Shanghai Cancer CenterShanghaiChina
  2. 2.Department of Oncology, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.School of Life SciencesFudan UniversityShanghaiChina

Personalised recommendations